Confo Therapeutics is a private company founded in 2015 by VIB, VUB (Jan Steyaert lab) and Capricorn Partners, with the support of MINTS, PMV, QBIC and V-Bio Ventures.
As an early-stage company moving towards clinical development, we have established a strong financial position backed by an impressive consortium of global investors including: BGV, Capricorn Partners, Fund+, Perceptive Advisors, PMV, University of Michigan, Qbic, V-Bio, VIB and Wellington Partners.
Our deals with big pharma further validate the novelty and potential of our GPCR drug discovery engine.